Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24114938 | 1.00 | GLS (0.40) | GLSITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL15125225 | 1.00 | GLS (0.40) | GLSITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL17192905 | 0.94 | GLS (0.36) | GLSALDH1A1TDP1RIPK1 | |
| SCHEMBL9658533 | 0.79 | GLS (0.40) | GLSITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL13317636 | 0.79 | — | — | |
| SCHEMBL24780845 | 0.79 | — | — | |
| SCHEMBL24780246 | 0.78 | GLS (0.37) | GLSITGB1ITGA4ITGB7RIPK1 | |
| SCHEMBL24780245 | 0.78 | GLS (0.37) | GLSITGB1ITGA4ITGB7RIPK1 | |
| SCHEMBL11246632 | 0.77 | — | — | |
| SCHEMBL1626773 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | GLS 2062/4885ITGB1 3953/4885ITGA4 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.